This study was supported by research funding from the National Natural Science Foundation of China (82230006, 82300169, 81970130, 82470159, and U24A20678), the Overseas Expertise Introduction Project ...

Acute promyelocytic leukemia (APL) is classically driven by the PML-RARA fusion oncogene and characterized by a maturation arrest of myeloid precursors. Variant APL (vAPL) with alternative RARA ...

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload ...

Patients who do not carry any of the aforementioned defining genetic alterations or whose pretreatment cytogenetic investigation fails are categorized into AML subtypes defined by differentiation. 7 ...

The three approved JAK inhibitors (ruxolitinib, fedratinib, and pacritinib) are the cornerstones of management for symptomatic myelofibrosis. Numerous novel agents in development for myelofibrosis, ...

Promyelocytic leukemia nuclear bodies (PML NBs) are multi-protein assemblies representing distinct sub-nuclear structures. As phase-separated molecular condensates, PML NBs exhibit liquid droplet-like ...

1Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine (Shanghai), Rui-Jin Hospital, Shanghai Jiao Tong University School of ...

Acute Promyelocytic Leukemia (APL) is one of the most curable leukemia which shows great sensitivity to all-trans retinoic acid (ATRA) although a small number of the patients present poor prognosis ...

All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of treatment with arsenic trioxide ...

Each human chromosome, shown here at a resolution of 400 bands per haploid genome, contains two specialized structures, a centromere and two telomeres. The centromere divides the chromosome into short ...